Patents by Inventor Jiong Lan

Jiong Lan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
    Publication number: 20230203060
    Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Jichen ZHAO, Wan HE, Zhubo LIU, Ling PENG, Lijian CAI, Leitao ZHANG, Chonglan LIN, Huabin YANG, Tao ZHANG, Jiong LAN
  • DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230139111
    Abstract: Provided are a dihydronaphthyridinone compound as shown in formula (I), which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. In addition, provided are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Xin LI, Lili TANG, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230084095
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 16, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • OXO SIX-MEMBERED CYCLOPYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
    Publication number: 20220363681
    Abstract: Provided is an oxygen-substituted six-membered ring pyrimidine compound with selective inhibitory effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, as represented by formula (I). The definition of each group or symbol in the formula is detailed in the specification. Moreover, a pharmaceutical composition containing the compound and an application thereof in the preparation of cancer drugs are also provided.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 17, 2022
    Inventors: Fusheng ZHOU, Tao JIANG, Wan HE, Zhubo LIU, Leitao ZHANG, Jiong LAN
  • POLYMORPH OF CDK9 INHIBITOR AND PREPARATION METHOD FOR POLYMORPH AND USE THEREOF
    Publication number: 20220315576
    Abstract: The present invention provides a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and use thereof. Specifically, disclosed are 4-(((4-(5-chloro-2-(((1R,4r)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)pyridine-4-yl)thiazole-2-yl)amino)methyl)tetrahydro-2H-pyrano-4-methylnitrile maleate or fumarate or polymorphs thereof and applications thereof. In addition, also disclosed are a pharmaceutical composition containing the substance and an application of the pharmaceutical composition.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 6, 2022
    Inventors: Fusheng ZHOU, Jinzhu ZHAO, Jiong LAN
  • OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20220251109
    Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 11, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Lijian CAI, Tao JIANG, Jichen ZHAO, Yingtao LIU, Jinzhu ZHAO, Leitao ZHANG, Zhubo LIU, Ling PENG, Wan HE, Huabin YANG, Tao ZHANG, Qian DING, Biao ZHENG, Qiang LV, Jiong LAN
  • BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220235032
    Abstract: A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
    Type: Application
    Filed: May 9, 2020
    Publication date: July 28, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Tao JIANG, Yingtao LIU, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220177462
    Abstract: A substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use of same in the preparation of a drug for treating a RIPK1-related diseases or conditions.
    Type: Application
    Filed: March 20, 2020
    Publication date: June 9, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Zhubo LIU, Gang HU, Qian DING, Fubo XIE, Biao ZHENG, Qiang LV, Jiong LAN
  • Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof
    Patent number: 11174254
    Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 16, 2021
    Assignees: YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD., SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shuchun Guo, Fusheng Zhou, Xiang Chen, Jinzhu Zhao, Dong Huang, Jing Xie, Changjiang Qiao, Wan He, Kai Zhang, Xi Chen, Jiong Lan
  • 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
    Patent number: 11155546
    Abstract: The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: October 26, 2021
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Shuchun Guo, Fusheng Zhou, Xiang Chen, Jinzhu Zhao, Dong Huang, Jing Xie, Changjiang Qiao, Wan He, Kai Zhang, Xi Chen, Jiong Lan
  • 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof
    Patent number: 11104664
    Abstract: Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, a preparation method therefor, and a use thereof.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 31, 2021
    Inventors: Jianbiao Peng, Yang Liu, Lixiao Wang, Zhihua Fang, Zonglei Fei, Xi Chen, Jiong Lan
  • N-sulfonyl benzamides as voltage-gated sodium channel inhibitors
    Patent number: 10815197
    Abstract: The present invention discloses an N-sulfonyl benzamide derivative with a heterocyclic substituent, and a preparation method therefor and a pharmaceutical application thereof. More specifically, the invention discloses a compound represented by formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug thereof, and a preparation method therefor and an application thereof. Refer to the specification for definitions of each group in the formula.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 27, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Fusheng Zhou, Jinzhu Zhao, Dong Huang, Jing Xie, Yi Hu, Qiang Lv
  • Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof
    Patent number: 10793549
    Abstract: The present invention relates to a sulfuryl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: October 6, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yunzhou Jin, Xiang Chen, Pengfei Cheng, Ping Bu, Leitao Zhang, Chong Wen, Yingtao Liu, Fusheng Zhou, Ming Weng, Jiong Lan
  • 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES
    Publication number: 20200262812
    Abstract: Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, a preparation method therefor, and a use thereof.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 20, 2020
    Inventors: Jianbiao PENG, Yang LIU, Lixiao WANG, Zhihua FANG, Zonglei FEI, Xi CHEN, Jiong LAN
  • 1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES
    Publication number: 20200262813
    Abstract: The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 20, 2020
    Inventors: Fusheng ZHOU, Xiaoyong SHI, Lixiao WANG, Feng XU, Jing XIE, Ping BU, Pengfei CHENG, Zhiyuan ZHANG, Nanping CAI, Jiong LAN
  • 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROLO[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVES AND USES THEREOF
    Publication number: 20200223846
    Abstract: The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Shuchun GUO, Fusheng ZHOU, Xiang CHEN, Jinzhu ZHAO, Dong HUANG, Jing XIE, Changjiang QIAO, Wan HE, Kai ZHANG, Xi CHEN, Jiong LAN
  • Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof
    Patent number: 10577346
    Abstract: It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 3, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fusheng Zhou, Shuchun Guo, Jinzhu Zhao, Hui Xu, Xia Shi, Yi Hu, Yufeng Li, Jiong Lan
  • EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
    Patent number: 10561646
    Abstract: Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 18, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Taotao Jiang, Daofei Li, Xing Liu
  • ANILINE-SUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE THEREOF
    Publication number: 20200048248
    Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.
    Type: Application
    Filed: August 3, 2018
    Publication date: February 13, 2020
    Inventors: Shuchun GUO, Fusheng ZHOU, Xiang CHEN, Jinzhu ZHAO, Dong HUANG, Jing XIE, Changjiang QIAO, Wan HE, Kai ZHANG, Xi CHEN, Jiong LAN
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
    Patent number: 10435400
    Abstract: The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 8, 2019
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Yunzhou Jin, Fusheng Zhou, Jing Xie, Sida Shen, Yi Hu, Wei Liu, Qiang Lv